Frequently Asked Questions
The market is segmented based on Segmentation, By Disease Type (CF Bronchiectasis, and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral, and Inhalation), End User (Hospitals, Clinics, Home Healthcare, and Others) – Industry Trends and Forecast to 2031
.
The Global Bronchiectasis Market size was valued at USD 562.92 USD Million in 2023.
The Global Bronchiectasis Market is projected to grow at a CAGR of 6.1% during the forecast period of 2024 to 2031.
The major players operating in the market include Abbott, HERSILL, Inogen , Boehringer Ingelheim International GmbH, Medline Industries , Ache Laboratories Farmaceuticos SA, Horizon Therapeutics plc, Janssen Pharmaceuticals , Trudell Medical International, GlaxoSmithKline plc, AstraZeneca, Pfizer , Merck Sharp & Dohme Corp., Novartis AG, Teva Pharmaceutical USA , Sun Pharmaceutical Industries Ltd, Bayer AG, Dr. Reddy's Laboratories Ltd, Sunovion Pharmaceuticals , Viatris , Covis Pharma, Zydus Pharmaceuticals , Cipla , Electromed .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
